Directory

RELLO CONDOMINES, Jordi

Department of Medicine

RELLO CONDOMINES, Jordi

CV

Teacher profile

Professor Catedràtic

Medicine, Faculty of Medicine and Health Sciences. Universitat Internacional de Catalunya

Research interests

Pneumonia, Sepsis, cures intensives, infeccions

Education

Jordi Rello has a Degree in Medicine and Surgery from the Universitat de Barcelona (1985). He specialized in Intensive Care at the Hospital Sant Pau de Barcelona (1990). He received postgraduate training in infection control and epidemiology of infectious diseases at Harvard Medical School, Boston. He holds a PhD Degree in Infectious Diseases from the Universitat de Barcelona (1990).

Professional experience

Currently, Jordi is Director of the Clinical Research & Innovation in Pneumonia and Sepsis (CRIPS) Group at Vall d'Hebron Research Institute & CIBERES: http://www.vhir.org/gr/crips, ubicated in Vall d’Hebron Barcelona Hospital Campus. He has conducted clinical practice as consultant, leaded research and trained fellows in critical care from 1990, with special focus on severe pneumonia & precision medicine in sepsis. After serving as critical care consultant in Hospital Clinic de Barcelona & Hospital Tauli in Sabadell, he became Head of the ICU Department in 1999 in the University Hospital de Tarragona and in 2000 at the University Hospital Vall d’Hebron, Barcelona. He has directed above 20 doctoral thesis, being part of his academic duties as Professor of Medicine at the Universitat Autònoma de Barcelona and Rovira & Virgili University in Tarragona. Currently, he is Professor of translational medicine at Institut de Recerca Vall d’Hebron and Full Professor of Medicine of the Universitat Internacional de Catalunya. He has > 550 indexed manuscripts with 40,629 citations (overall 2,850 per year from 2013). He has been awarded in 2018 as international honorary professor of CSCCM – Chinese Medical Association.

Publications

Articles

Projects and research

  • Ensayo de fase II aleatorizado, doble ciego y controlado con placebo de la combinación del anticuerpo monoclonal MHAA4549A con oseltamivir frente a oseltamivir por sí solo para el tratamiento de la infección por gripe A grave14/01/2015
    IP: CLINICO , H.
    Genentech
  • Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis (SCOTCH;)01/01/2015
    IP: FERNANDEZ, J.
    Universitaire Ziekenhuizen KU Leuven
  • Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)01/05/2012
    IP: LATERRE, P.
    Aridis Pharmaceuticals, Inc.
  • A randomized, double-blind, placebo-controlled, multicenter, parallel-group, adaptive group-sequential phase II study, to determine the efficacy and safety of BT086 as an adjunctive treatment in severe community acquired pneumonia (sCAP)04/10/2011
    IP: Rello, J.
    Biotest AG
  • Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock28/04/2009
    IP: WUNDERINK, R.
    Eli Lilly
  • Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients01/12/2008
    IP: HAAS, N.
    Valneva Austria GmbH
  • Neumonía asociada a la ventilación mecánica: Efectividad de la implementación del 'feedback' sobre cumplimiento de un paquete de medidas para mejorar la seguridad de los pacientes en UCI (FADO-2)01/01/2008
    IP: Rello, J.
    Fundació Privada Hospital Joan XXIII
  • Estudio de prevalencia de la infección en Cuidados Intensivos (EPIC II)08/05/2007
    IP: VINCENT, J.
    European Society of Intensive Care Medicine
  • GENOSEPT Genetics of Sepsis in Europe01/01/2005
    IP: MATHY, N.
    European Society of Intensive Care Medicine